References
- Chikhale, R. V., Sinha, S. K., Patil, R. B., & Prasad, S. K. (2020). In-silico investigation of phytochemicals from Asparagus racemosus as plausible antiviral agent in COVID-19. Journal of Biomolecular Structure and Dynamics, 1–15.
- Cuschieri, S., & Grech, S. (2020). COVID-19 and diabetes: The why, the what and the how. Journal of Diabetes and Its Complications, 34(9), 107637. https://doi.org/https://doi.org/10.1016/j.jdiacomp.2020.107637
- Daina, A., Michielin, O., & Zoete, V. (2017). SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific Reports, 7, 42717. https://doi.org/https://doi.org/10.1038/srep42717
- Das, S., K R, A., Birangal, S. R., Nikam, A. N., Pandey, A., Mutalik, S., & Joseph, A. (2020). Role of comorbidities like diabetes on severe acute respiratory syndrome coronavirus-2: A review. Life Sciences, 258, 118202. https://doi.org/https://doi.org/10.1016/j.lfs.2020.118202
- Design, L. (2014). Pharmacophore and ligand-based design with Biovia Discovery StudioV.
- Dhama, K., Sharun, K., Tiwari, R., Dadar, M., Malik, Y. S., Singh, K. P., & Chaicumpa, W. (2020). COVID-19, an emerging coronavirus infection: Advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics. Human Vaccines & Immunotherapeutics, 16(6), 1232–1238. https://doi.org/https://doi.org/10.1080/21645515.2020.1735227
- Harrison, C. (2020). Coronavirus puts drugs repurposing on the fast track. Nature Biotechnology, 38(4), 379–381. https://doi.org/https://doi.org/10.1038/d41587-020-00003-1
- Hastantram, M., Ramaiah, S., Vishwakarma, R., & Shaanker, R. U. (2020). Molecular docking analysis of selected natural products from plants for inhibition of SARS-CoV-2 main protease. Current Science, 118 (7), 1087–1092.
- Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., Müller, M. A., Drosten, C., & Pöhlmann, S. (2020). SARS-CoV-2 cell entry depends on ACE-2 and TMPRSS2 and is blocked by Clinically proven protease inhibitors. Cell, 181(2), 271–210. https://doi.org/https://doi.org/10.1016/j.cell.2020.02.052
- Huang, B. (2009). MetaPocket: A meta approach to improve protein ligand binding site prediction. Omics : A Journal of Integrative Biology, 13(4), 325–330. https://doi.org/https://doi.org/10.1089/omi.2009.0045
- Iacobellis, G. (2020). COVID-19 and diabetes: Can DPP4 inhibition play a role? Diabetes Research and Clinical Practice, 162, 108125. https://doi.org/https://doi.org/10.1016/j.diabres.2020.108125
- Kilanski, A., & Baker, S. C. (2015). Cell-based antiviral screening against coronaviruses: Developing virus-specific and broad-spectrum inhibitors. Antiviral Research, 116, 76–84.
- Li, G., & Clercq, E. D. (2020). Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nature Reviews, 19(3), 149–150. https://doi.org/https://doi.org/10.1038/d41573-020-00016-0.
- Lin, L., Lu, L., Cao, W., & Li, T. (2020). Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia. Emerging Microbes & Infections, 9(1), 727–732. https://doi.org/https://doi.org/10.1080/22221751.2020.1746199
- Liu, C., Zhou, Q., Li, Y., Garner, L. V., Watkins, S. P., Carter, L. J., Smoot, J., Gregg, A. C., Daniels, A. D., Jervey, S., & Albaiu, D. (2020). Research and development on therapeutic agents and vaccines for COVID-19 and related human Coronavirus Diseases. ACS Central Science, 6(3), 315–331. https://doi.org/https://doi.org/10.1021/acscentsci.0c00272
- Mandadapu, S. R., Weerawarna, P. M., Prior, A. M., Uy, R. A. Z., Aravapalli, S., Alliston, K. R., Lushington, G. H., Kim, Y., Hua, D. H., Chang, K.-O., & Groutas, W. C. (2013). Macrocyclic inhibitors of 3C an 3CL-like proteases of picornavirus, norovirus, and coronavirus. Bioorganic & Medicinal Chemistry Letters, 23(13), 3709–3712. https://doi.org/https://doi.org/10.1016/j.bmcl.2013.05.021
- Matsumyama, S., Nao, N., Shirato, K., Kawase, M. M., & Saito, S. (2020). Enhanced isolation of SARS-CoV-2 by TMPRSS2 expressing cells. Proceedings of the National Academy of Sciences of the United States of America, 117(13), 7001-7003. https://doi.org/https://doi.org/10.1073/pnas.2002589117
- Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S., & Olson, A. J. (2009). AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. Journal of Computational Chemistry, 30(16), 2785–2791. https://doi.org/https://doi.org/10.1002/jcc.21256
- Muniyappa, R., & Gubbi, S. (2020). COVID-19 pandemic, coronaviruses, and diabetes mellitus. American Journal of Physiology. Endocrinology and Metabolism, 318(5), E736–E741. https://doi.org/https://doi.org/10.1152/ajpendo.00124.2020
- Narkhede, R. R., Cheke, S. R., Jaya, P. A., & Shinde, S. D. (2020). The molecular docking study of potential drug candidates showing anti-COVID-19 activity by exploring of therapeutic targets of SARS-CoV-2. EJMO, 4(3), 185–195.
- O’Boyle, N. M., Banck, M., James, C. A., Morley, C., Vandermeersch, T., & Hutchison, G. R. (2011). Open Babel: An open chemical toolbox. Journal of Cheminformatics, 3, 33. https://doi.org/https://doi.org/10.1186/1758-2946-3-33
- Prajapat, M., Sarma, P., Shekhar, N., Avti, P., Sinha, S., Kaur, H., Kumar, S., Bhattacharyya, A., Kumar, H., Bansal, S., & Medhi, B. (2020). Drug targets for corona virus: A systematic review. The Indian Journal of Pharmacology, 52(1), 56–65. https://doi.org/https://doi.org/10.4103/ijp.IJP_115_20
- Prasanth, D., Murahari, M., Chandramohan, V., Panda, S. P., & Atmakuri, L. R. (2020). In silico identification of potential inhibitors from Cinnamon against main protease and spike glycoprotein of SARS CoV-2. Journal of Biomolecular Structure and Dynamics, 1–15. https://doi.org/https://doi.org/10.1080/07391102.2020.1779129
- Quimque, M. T. J., Notarte, K. I. R., & Fernandez, R. A. T. (2020). Virtual screening-driven drug discovery of SARS-CoV2 enzyme inhibitors targeting viral attachment, replication, post-translational modification and host immunity evasion infection mechanisms. Journal of Biomolecular Structure and Dynamics, 1–18. https://doi.org/https://doi.org/10.1080/07391102.2020.1776639
- Sheahan, T. P., Sims, A. C., Leist, S. R., Schäfer, A., Won, J., Brown, A. J., Montgomery, S. A., Hogg, A., Babusis, D., Clarke, M. O., Spahn, J. E., Bauer, L., Sellers, S., Porter, D., Feng, J. Y., Cihlar, T., Jordan, R., Denison, M. R., & Baric, R. S. (2020). Comparative therapeutic efficacy of remedesirir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nature Communications, 11(1), 1-14. https://doi.org/https://doi.org/10.1038/s41467-019-13940-6
- Singh, A. K., Gupta, R., & Misra, A. (2020). Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers. Diabetes & Metabolic Syndrome, 14(4), 283–287. https://doi.org/https://doi.org/10.1016/j.dsx.2020.03.016
- Solaimanzadeh, I. (2020). Acetazolamide, nifedipine and phosphodiesterase inhibitors: Rationale for their utilization as adjunctive countermeasures in the treatment of Coronavirus Disease 2019 (COVID-19). Cureus, 12(3), e7343. https://doi.org/https://doi.org/10.7759/cureus.7343
- Song, W., Wang, Y., Wang, N., Wang, D., Guo, J., Fu, L., & Shi, X. (2014). Identification of residues on human receptor DPP4 critical for MERS-CoV binding and entry. Virology, 471-473, 49–53. https://doi.org/https://doi.org/10.1016/j.virol.2014.10.006
- Talukdar, S. N., & Hossain, M. N. (2014). Phytochemical, phytotherapeutical and pharmacological study of Momordica dioica. Evidence Based Complementary Alternative Medicine, 2014, 806082. https://doi.org/https://doi.org/10.1155/2014/806082
- Thiruvengadam, M., Rekha, K., & Chung, I. M. (2016). Induction of hairy roots by Agrobacterium rhizogenes-mediated transformation of spine gourd (Momordica dioica Roxb. ex. willd) for the assessment of phenolic compounds and biological activities. Scientia Horticulturae, 198, 132–141. https://doi.org/https://doi.org/10.1016/j.scienta.2015.11.035
- Totura, A. L., & Bavari, S. (2019). Broad-spectrum coronavirus antiviral drug discovery. Expert Opinion on Drug Discovery, 14(4), 397–412. https://doi.org/https://doi.org/10.1080/17460441.2019.1581171
- Trott, O., & Olson, A. J. (2020). AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of Computational Chemistry, 31(2), 455–461.
- Valencia, I., Peiro, C., Lorenzo, O., Sanchez-Ferrer, C. F., Eckel, J., & Romacho, T. (2020). DPP4 and ACE2 in diabetes and COVID-19: Therapeutic targets for cardiovascular complications? Frontiers in Pharmacology, 11, 1161. https://doi.org/https://doi.org/10.3389/fphar.2020.01161
- Vankadari, N., & Wilce, J. A. (2020). Emerging WuHan (COVID-19) coronavirus: Glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26. Emerging Microbes and Infection, 9(1), 601–604. https://doi.org/https://doi.org/10.1080/22221751.2020.1739565
- Vijayakumar, B. G., Ramesh, D., Joji, A., Prakasan, J. J., & Kannan, T. (2020). In silico pharmacokinetic and molecular docking studies of natural flavonoids and synthetic indole chalcones against essential proteins of SARS-CoV-2. European Journal of Pharmacology, 886, 173448. https://doi.org/https://doi.org/10.1016/j.ejphar.2020.173448
- Wishart, D. S., Knox, C., Guo, A. C., Shrivastava, S., Hassanali, M., Stothard, P., Chang, Z., & Woolsey, J. (2006). Drugbank: A comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Research, 34(Database issue), D668–72. (Database issue):16381955. https://doi.org/https://doi.org/10.1093/nar/gkj067
- Yang, Y., Shen, C., Li, J., Yuan, J., Yang, M., & Wang, F. (2020). Exuberant elevation of IP-10, MCP-3 and IL-1ra during SARS-CoV-2 infection is associated with disease severity and fatal outcome. medRxiv. https://doi.org/https://doi.org/10.1101/2020.03.02.20029975
- Zhang, W., Zhao, Y., Zhang, F., Wang, Q., Li, T., Liu, Z., Wang, J., Qin, Y., Zhang, X., Yan, X., Zeng, X., & Zhang, S. (2020). Anti-inflammation treatment of severe coronavirus disease 2019 (COVID-19): from the perspective of clinical immunologists from China. Clinical Immunology (Orlando, FLA.), 214, 108393. https://doi.org/https://doi.org/10.1016/j.clim.2020.108393
- Zhou, Y., Hou, Y., Shen, J., Huang, Y., Martin, W., & Cheng, F. (2020). Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discovery, 6, 14. https://doi.org/https://doi.org/10.1038/s41421-020-0153-3
- Zou, H., Zhu, N., & Li, S. (2020). The emerging role of dipeptidyl-peptidase-4 as a therapeutic target in lung disease. Expert Opinion on Therapeutic Targets, 24(2), 147–153. https://doi.org/https://doi.org/10.1080/14728222.2020.1721468